Korsana Biosciences, Inc.
KRSA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$32.09
KIRA · Stoqly’s AI analyst, in plain words
- Korsana Biosciences, Inc. had $2.1M of revenue in fiscal 2025, up 3.7% on the year before. Over five years, revenue changed −2.0% a year on average.
- Its operating margin was −239.8%, down 58.4 pts: of every 100 in sales, about −240 is left after running the business.
- Korsana Biosciences, Inc. lost $3.5M in fiscal 2025.
Market cap
$136M
P/E
—
Revenue
$2.1M
Net income
−$3.5M
Free cash flow
—
Operating margin
−239.8%
Korsana Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+3.7%
Only a little. Sales grew 3.7% last year.
Does it make a profit?
−170.1%
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Korsana Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Korsana Biosciences, Inc.
- CIK
- 0001755237
Korsana Biosciences, Inc. · KRSA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.9M | $0.3M | $0.0M | $2.0M | $2.1M |
| Revenue growth | 71.7% | −92.5% | −100.0% | — | 3.7% |
| Operating margin | −1,400.2% | −6,242.4% | — | −181.4% | −239.8% |
| Net income | −$51.6M | −$44.1M | −$5.3M | −$3.1M | −$3.5M |
| Net margin | −1,310.2% | −14,841.1% | — | −152.9% | −170.1% |
| Diluted EPS | −$1.32 | −$20.28 | −$2.25 | −$1.21 | −$1.11 |
| Cash | |||||
| Cash from operations | −$36.5M | −$40.6M | −$21.2M | −$4.3M | −$3.3M |
| Capital expenditure | $0.0M | $0.0M | — | — | — |
| Free cash flow | −$36.5M | −$40.6M | — | — | — |
| FCF margin | −926.5% | −13,673.7% | — | — | — |
| Share count change | 28.8% | −94.4% | 7.6% | 7.7% | 26.3% |
| Debt and strength | |||||
| Cash and short-term investments | $54.0M | $13.4M | $7.6M | $3.2M | $3.2M |
| Debt incl. finance leases | $3.5M | $3.5M | — | — | — |
| Shareholders' equity | $48.2M | $10.5M | $11.3M | $8.9M | $9.1M |
| Current ratio | 5.0x | 1.9x | 3.8x | 5.8x | 5.2x |
| Returns and quality | |||||
| Return on capital | — | −2,569.6% | — | — | — |
| Return on equity | −95.9% | −150.2% | −48.4% | −30.4% | −39.3% |
| Return on tangible equity | −107.0% | −421.7% | −46.6% | −34.5% | −38.8% |
| Piotroski F-score | 3 | 2 | 2 | 3 | 1 |
| Altman Z'' | −8.6 | −49.6 | −62.4 | −78.4 | −78.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Korsana Biosciences, Inc. · KRSA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $32.09 a share, the company is worth $136M.
Source: SEC EDGAR XBRL filings (CIK 0001755237). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.